- Use of selective serotonin reuptake inhibitor (SSRI) during pregnancy is associated with an increased risk for persistent pulmonary hypertension of the newborn (PPHN).
- Risk for PPHN associated with SSRI use might not warrant the withdrawal of therapy, as previous studies showed that untreated perinatal depression presents additional adverse outcomes.
Why this matters
- The prevalence of maternal depression, and consequent use of antidepressants is rising worldwide.
- The use of SSRIs during pregnancy to treat antenatal depression remains a challenge.
- Meta-analysis of 9 studies, involving 7,540,265 women with SSRIs use during pregnancy, identified after search across electronic databases.
- Funding: None.
- Using random effects model, the pooled results of 8 trials showed that use of SSRI during pregnancy was associated with increased risk for PPHN (OR, 1.516; 95% CI, 1.035-1.997; P<.001>
- Overall, the absolute increase in risk for PPHN with SSRI use was small with an absolute risk difference of 0.619/1000 livebirth and a number needed to harm of 1615 women.
- All potential confounders were not adjusted.
- Diagnostic criteria and definition of PPHN differed among studies.